

Jesus M Banales

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4896725/publications.pdf>

Version: 2024-02-01

180
papers

10,668
citations

34016

52
h-index

39575

94
g-index

185
all docs

185
docs citations

185
times ranked

12023
citing authors

#	ARTICLE	IF	CITATIONS
1	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	8.2	1,155
2	Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 261-280.	8.2	964
3	Mutations in GANAB , Encoding the Glucosidase II± Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. <i>American Journal of Human Genetics</i> , 2016, 98, 1193-1207.	2.6	345
4	Wnt-β-catenin signalling in liver development, health and disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 121-136.	8.2	341
5	Cholangiocyte pathobiology. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 269-281.	8.2	285
6	Biliary exosomes influence cholangiocyte regulatory mechanisms and proliferation through interaction with primary cilia. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, G990-G999.	1.6	234
7	Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. <i>Hepatology</i> , 2017, 66, 1125-1143.	3.6	218
8	Up-regulation of microRNA 506 leads to decreased Cl ⁻ /HCO ₃ ⁻ anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. <i>Hepatology</i> , 2012, 56, 687-697.	3.6	199
9	Cholangiocyte cilia express TRPV4 and detect changes in luminal tonicity inducing bicarbonate secretion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 19138-19143.	3.3	186
10	Ae2-Deficient Mice Develop Antimitochondrial Antibodies and Other Features Resembling Primary Biliary Cirrhosis. <i>Gastroenterology</i> , 2008, 134, 1482-1493.	0.6	183
11	MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. <i>Journal of Clinical Investigation</i> , 2008, 118, 3714-3724.	3.9	158
12	Cholangiocyte primary cilia are chemosensory organelles that detect biliary nucleotides via P2Y ₁₂ purinergic receptors. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 295, G725-G734.	1.6	147
13	Metabolic rearrangements in primary liver cancers: cause and consequences. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 748-766.	8.2	144
14	Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids. <i>Cell Stem Cell</i> , 2021, 28, 816-832.	5.2	133
15	Bile Acids in Physiology, Pathology and Pharmacology. <i>Current Drug Metabolism</i> , 2015, 17, 4-29.	0.7	131
16	Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. <i>Journal of Hepatology</i> , 2017, 66, 102-115.	1.8	130
17	Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. <i>Hepatology</i> , 2013, 58, 1065-1073.	3.6	124
18	Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 67, 282-292.	1.8	123

#	ARTICLE	IF	CITATIONS
19	Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1430-1439.	0.6	123
20	Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. <i>Journal of Hepatology</i> , 2022, 76, 1109-1121.	1.8	119
21	Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. <i>Hepatology Communications</i> , 2018, 2, 807-820.	2.0	117
22	Cholangiocyte anion exchange and biliary bicarbonate excretion. <i>World Journal of Gastroenterology</i> , 2006, 12, 3496.	1.4	114
23	Clinical management of polycystic liver disease. <i>Journal of Hepatology</i> , 2018, 68, 827-837.	1.8	112
24	Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2019, 70, 547-562.	3.6	112
25	The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). <i>Hepatology</i> , 2009, 49, 160-174.	3.6	110
26	Development and Validation of Hepamet Fibrosis Scoring System—A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 216-225.e5.	2.4	104
27	Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. <i>Gut</i> , 2016, 65, 1535-1545.	6.1	103
28	Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. <i>Hepatology</i> , 2013, 58, 409-421.	3.6	96
29	Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger. <i>Hepatology</i> , 2006, 43, 266-275.	3.6	93
30	Methods for extracellular vesicles isolation in a hospital setting. <i>Frontiers in Immunology</i> , 2015, 6, 50.	2.2	93
31	miRNA-21 ablation protects against liver injury and necroptosis in cholestasis. <i>Cell Death and Differentiation</i> , 2018, 25, 857-872.	5.0	92
32	Diagnostic and prognostic biomarkers in cholangiocarcinoma. <i>Liver International</i> , 2019, 39, 108-122.	1.9	89
33	The challenges of primary biliary cholangitis: What is new and what needs to be done. <i>Journal of Autoimmunity</i> , 2019, 105, 102328.	3.0	86
34	Activation of Trpv4 Reduces the Hyperproliferative Phenotype of Cystic Cholangiocytes From an Animal Model of ARPKD. <i>Gastroenterology</i> , 2010, 139, 304-314.e2.	0.6	85
35	SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. <i>Journal of Hepatology</i> , 2017, 67, 72-83.	1.8	81
36	Dual Targeting of Histone Methyltransferase G9a and DNA Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 587-603.	3.6	81

#	ARTICLE	IF	CITATIONS
37	Polycystic liver diseases: advanced insights into the molecular mechanisms. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 750-761.	8.2	80
38	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. <i>Journal of Hepatology</i> , 2021, 74, 20-30.	1.8	77
39	Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 497-511.	8.2	73
40	Hepatic Cystogenesis Is Associated with Abnormal Expression and Location of Ion Transporters and Water Channels in an Animal Model of Autosomal Recessive Polycystic Kidney Disease. <i>American Journal of Pathology</i> , 2008, 173, 1637-1646.	1.9	72
41	MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation. <i>Hepatology</i> , 2018, 67, 1420-1440.	3.6	72
42	The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1468-1477.	1.8	72
43	Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	72
44	The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1260-1270.	1.9	70
45	Cocarcinogenic Effects of Intrahepatic Bile Acid Accumulation in Cholangiocarcinoma Development. <i>Molecular Cancer Research</i> , 2014, 12, 91-100.	1.5	65
46	Post-translational Regulation of the Type III Inositol 1,4,5-Trisphosphate Receptor by miRNA-506. <i>Journal of Biological Chemistry</i> , 2015, 290, 184-196.	1.6	65
47	Pyroptosis: An inflammatory link between NAFLD and NASH with potential therapeutic implications. <i>Journal of Hepatology</i> , 2018, 68, 643-645.	1.8	64
48	Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis. <i>Cells</i> , 2020, 9, 721.	1.8	63
49	Pathogenesis of Cholangiocarcinoma. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2021, 16, 433-463.	9.6	63
50	PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery. <i>Surgery for Obesity and Related Diseases</i> , 2016, 12, 1838-1846.	1.0	60
51	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. <i>Journal of Hepatology</i> , 2020, 73, 17-25.	1.8	59
52	TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms. <i>Gut</i> , 2021, 70, 1345-1361.	6.1	59
53	Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. <i>Journal of Hepatology</i> , 2015, 63, 952-961.	1.8	56
54	RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease. <i>Gut</i> , 2021, 70, 2359-2372.	6.1	56

#	ARTICLE	IF	CITATIONS
55	Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases. <i>Gut</i> , 2014, 63, 1658-1667.	6.1	55
56	Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1335-1344.	1.8	55
57	MicroRNA (miR)â€433 and miRâ€22 dysregulations induce histoneâ€deacetylaseâ€6 overexpression and ciliary loss in cholangiocarcinoma. <i>Hepatology</i> , 2018, 68, 561-573.	3.6	54
58	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. <i>Human Molecular Genetics</i> , 2022, 31, 3945-3966.	1.4	46
59	Type 3 Inositol 1,4,5â€Trisphosphate Receptor Is Increased and Enhances Malignant Properties in Cholangiocarcinoma. <i>Hepatology</i> , 2020, 71, 583-599.	3.6	45
60	Matrix metalloproteinaseâ€10 expression is induced during hepatic injury and plays a fundamental role in liver tissue repair. <i>Liver International</i> , 2014, 34, e257-70.	1.9	43
61	Nlrp3 Activation Induces Il-18 Synthesis and Affects the Epithelial Barrier Function in Reactive Cholangiocytes. <i>American Journal of Pathology</i> , 2017, 187, 366-376.	1.9	43
62	Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial. <i>Journal of Hepatology</i> , 2016, 65, 601-607.	1.8	41
63	Causes of hOCT1â€Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumorâ€Selective Gene Therapy. <i>Hepatology</i> , 2019, 70, 1246-1261.	3.6	41
64	Lignins from Agroindustrial by-Products as Natural Ingredients for Cosmetics: Chemical Structure and In Vitro Sunscreen and Cytotoxic Activities. <i>Molecules</i> , 2020, 25, 1131.	1.7	41
65	Inhibition of Cdc25A Suppresses Hepato-renal Cystogenesis in Rodent Models of Polycystic Kidney and Liver Disease. <i>Gastroenterology</i> , 2012, 142, 622-633.e4.	0.6	40
66	Italian Clinical Practice Guidelines on Cholangiocarcinoma â€“ Part I: Classification, diagnosis and staging. <i>Digestive and Liver Disease</i> , 2020, 52, 1282-1293.	0.4	40
67	Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. <i>Hepatology</i> , 2021, 73, 2311-2325.	3.6	40
68	Epigenetic events involved in organic cation transporter 1â€dependent impaired response of hepatocellular carcinoma to sorafenib. <i>British Journal of Pharmacology</i> , 2019, 176, 787-800.	2.7	39
69	MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis. <i>Cell Death and Disease</i> , 2018, 9, 958.	2.7	38
70	Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach. <i>Cancers</i> , 2020, 12, 1644.	1.7	38
71	Novel genes and sex differences in COVID-19 severity. <i>Human Molecular Genetics</i> , 2022, 31, 3789-3806.	1.4	38
72	Shared apical sorting of anion exchanger isoforms AE2a, AE2b1, and AE2b2 in primary hepatocytes. <i>Biochemical and Biophysical Research Communications</i> , 2004, 319, 1040-1046.	1.0	37

#	ARTICLE	IF	CITATIONS
73	Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1492-1500.	0.6	37
74	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. <i>British Journal of Cancer</i> , 2020, 123, 1047-1059.	2.9	37
75	Bicarbonate secretion of mouse cholangiocytes involves Na ⁺ -HCO ₃ ⁻ cotransport in addition to Na ⁺ -independent Cl ⁻ /HCO ₃ ⁻ exchange. <i>Hepatology</i> , 2010, 51, 891-902.	3.6	36
76	Extracellular Vesicles in NAFLD/ALD: From Pathobiology to Therapy. <i>Cells</i> , 2020, 9, 817.	1.8	36
77	MicroRNAs and cholestatic liver diseases. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 303-309.	1.0	35
78	Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?. <i>Journal of Hepatology</i> , 2018, 69, 1371-1383.	1.8	35
79	Italian Clinical Practice Guidelines on Cholangiocarcinoma – Part II: Treatment. <i>Digestive and Liver Disease</i> , 2020, 52, 1430-1442.	0.4	35
80	Histone deacetylase 4 promotes cholestatic liver injury in the absence of prohibitin1. <i>Hepatology</i> , 2015, 62, 1237-1248.	3.6	34
81	Elevated interleukin-8 in bile of patients with primary sclerosing cholangitis. <i>Liver International</i> , 2016, 36, 1370-1377.	1.9	34
82	Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD. <i>Frontiers in Medicine</i> , 2021, 8, 683250.	1.2	34
83	Ursodeoxycholic Acid Is Conjugated with Taurine to Promote Secretin-Stimulated Biliary Hydrocholeresis in the Normal Rat. <i>PLoS ONE</i> , 2011, 6, e28717.	1.1	34
84	Fine-tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease. <i>Hepatology</i> , 2019, 69, 699-716.	3.6	33
85	The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma. <i>EBioMedicine</i> , 2021, 73, 103661.	2.7	31
86	MicroRNAs in biliary diseases. <i>World Journal of Gastroenterology</i> , 2012, 18, 6189.	1.4	30
87	Anion exchanger 2 is critical for CD8 ⁺ T cells to maintain pH _i homeostasis and modulate immune responses. <i>European Journal of Immunology</i> , 2014, 44, 1341-1351.	1.6	30
88	Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT). <i>Journal of Controlled Release</i> , 2015, 216, 93-102.	4.8	30
89	Extracellular Vesicles in Hepatobiliary Malignancies. <i>Frontiers in Immunology</i> , 2018, 9, 2270.	2.2	29
90	FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted. <i>Journal of Hepatology</i> , 2021, 75, 363-376.	1.8	29

#	ARTICLE	IF	CITATIONS
91	Effects of Endotoxin on Type 3 Inositol 1,4,5-Trisphosphate Receptor in Human Cholangiocytes. <i>Hepatology</i> , 2019, 69, 817-830.	3.6	28
92	Genetics of polycystic liver diseases. <i>Current Opinion in Gastroenterology</i> , 2019, 35, 65-72.	1.0	26
93	Dual Targeting of G9a and DNA Methyltransferase 1 for the Treatment of Experimental Cholangiocarcinoma. <i>Hepatology</i> , 2021, 73, 2380-2396.	3.6	26
94	RIPK1 and death receptor signaling drive biliary damage and early liver tumorigenesis in mice with chronic hepatobiliary injury. <i>Cell Death and Differentiation</i> , 2019, 26, 2710-2726.	5.0	23
95	Epigenomic Evaluation of Cholangiocyte Transforming Growth Factor- β Signaling Identifies a Selective Role for Histone 3 Lysine 9 Acetylation in Biliary Fibrosis. <i>Gastroenterology</i> , 2021, 160, 889-905.e10.	0.6	23
96	Oral Methylthioadenosine Administration Attenuates Fibrosis and Chronic Liver Disease Progression in Mdr2 ^{-/-} Mice. <i>PLoS ONE</i> , 2010, 5, e15690.	1.1	23
97	Activation of the developmental pathway neurogenin-3/microRNA-7a regulates cholangiocyte proliferation in response to injury. <i>Hepatology</i> , 2014, 60, 1324-1335.	3.6	22
98	Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets. <i>Liver International</i> , 2020, 40, 1670-1685.	1.9	22
99	Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?. <i>Liver Cancer</i> , 2021, 10, 545-560.	4.2	22
100	Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis. <i>Molecular Metabolism</i> , 2021, 53, 101275.	3.0	22
101	Methionine adenosyltransferase 1a antisense oligonucleotides activate the liver-brown adipose tissue axis preventing obesity and associated hepatosteatosis. <i>Nature Communications</i> , 2022, 13, 1096.	5.8	22
102	TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation. <i>Journal of Hepatology</i> , 2022, 77, 991-1004.	1.8	22
103	Severity in polycystic liver disease is associated with aetiology and female gender: Results of the International PLD Registry. <i>Liver International</i> , 2019, 39, 575-582.	1.9	21
104	Biliary secretion of S-nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat. <i>Hepatology</i> , 2010, 52, 667-677.	3.6	20
105	Novel equation to determine the hepatic triglyceride concentration in humans by MRI: diagnosis and monitoring of NAFLD in obese patients before and after bariatric surgery. <i>BMC Medicine</i> , 2014, 12, 137.	2.3	20
106	MicroRNAs in cholangiopathies: Potential diagnostic and therapeutic tools. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 15-27.	0.7	20
107	A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2020, 12, 1433.	1.7	20
108	Synergistic effects of extracellular vesicle phenotyping and AFP in hepatobiliary cancer differentiation. <i>Liver International</i> , 2020, 40, 3103-3116.	1.9	20

#	ARTICLE	IF	CITATIONS
109	Next-Generation Biomarkers for Cholangiocarcinoma. <i>Cancers</i> , 2021, 13, 3222.	1.7	20
110	Zinc Finger E2F Binding Homeobox 1 Promotes Cholangiocarcinoma Progression Through Tumor Dedifferentiation and Tumor-Stroma Paracrine Signaling. <i>Hepatology</i> , 2021, 74, 3194-3212.	3.6	20
111	The significance of genetics for cholangiocarcinoma development. <i>Annals of Translational Medicine</i> , 2013, 1, 28.	0.7	20
112	Centrosomal Abnormalities Characterize Human and Rodent Cystic Cholangiocytes and Are Associated with Cdc25A Overexpression. <i>American Journal of Pathology</i> , 2014, 184, 110-121.	1.9	19
113	Novel lncRNA T-UCR as a potential downstream driver of the Wnt/ β -catenin pathway in hepatobiliary carcinogenesis. <i>Gut</i> , 2017, 66, 1177-1178.	6.1	19
114	Nuclear Translocation of RELB Is Increased in Diseased Human Liver and Promotes Ductular Reaction and Biliary Fibrosis in Mice. <i>Gastroenterology</i> , 2019, 156, 1190-1205.e14.	0.6	19
115	MRP3-Mediated Chemoresistance in Cholangiocarcinoma: Target for Chemosensitization Through Restoring SOX17 Expression. <i>Hepatology</i> , 2020, 72, 949-964.	3.6	19
116	Neutrophils interact with cholangiocytes to cause cholestatic changes in alcoholic hepatitis. <i>Gut</i> , 2021, 70, gutjnl-2020-322540.	6.1	19
117	miRNA profiling of biliary intraepithelial neoplasia reveals stepwise tumorigenesis in distal cholangiocarcinoma via the miR-451a/ATF2 axis. <i>Journal of Pathology</i> , 2020, 252, 239-251.	2.1	18
118	Primary biliary cholangitis: pathogenic mechanisms. <i>Current Opinion in Gastroenterology</i> , 2021, 37, 91-98.	1.0	18
119	Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma. <i>American Journal of Pathology</i> , 2019, 189, 2090-2101.	1.9	17
120	Measurement of Liver Iron Concentration by MRI Is Reproducible. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	15
121	Effect of pravastatin on the survival of patients with advanced gastric cancer. <i>Oncotarget</i> , 2016, 7, 4379-4384.	0.8	15
122	Novel causative genes for polycystic liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 391-392.	8.2	15
123	Cholangiocarcinoma progression depends on the uptake and metabolism of extracellular lipids. <i>Hepatology</i> , 2022, 76, 1617-1633.	3.6	15
124	Long non-coding RNA ACTA2-AS1 promotes ductular reaction by interacting with the p300/ELK1 complex. <i>Journal of Hepatology</i> , 2022, 76, 921-933.	1.8	15
125	Genetics, pathobiology and therapeutic opportunities of polycystic liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 585-604.	8.2	15
126	CXCR7 contributes to the aggressive phenotype of cholangiocarcinoma cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 2246-2256.	1.8	14

#	ARTICLE	IF	CITATIONS
127	Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial). <i>Cancers</i> , 2020, 12, 1900.	1.7	14
128	Melatonin Protects Cholangiocytes from Oxidative Stress-Induced Proapoptotic and Proinflammatory Stimuli via miR-132 and miR-34. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9667.	1.8	14
129	Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models. <i>Journal of Hepatology</i> , 2021, 74, 394-406.	1.8	14
130	Extracellular Vesicles in Liver Diseases: Meeting Report from the International Liver Congress 2018. <i>Hepatology Communications</i> , 2019, 3, 305-315.	2.0	13
131	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. <i>Liver International</i> , 2021, 41, 2076-2086.	1.9	13
132	Multi-Omics Integration Highlights the Role of Ubiquitination in CCl4-Induced Liver Fibrosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9043.	1.8	12
133	Extracellular Signal-Regulated Kinase 5 Regulates the Malignant Phenotype of Cholangiocarcinoma Cells. <i>Hepatology</i> , 2021, 74, 2007-2020.	3.6	12
134	Optimizing the use of twitter for research dissemination: The "Three Facts and a Story" randomized-controlled trial. <i>Journal of Hepatology</i> , 2021, 75, 271-274.	1.8	12
135	YAP Accelerates Notch-Driven Cholangiocarcinogenesis via mTORC1 in Mice. <i>American Journal of Pathology</i> , 2021, 191, 1651-1667.	1.9	12
136	Novel GANAB variants associated with polycystic liver disease. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 302.	1.2	11
137	Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models. <i>Journal of Hepatology</i> , 2022, 77, 177-190.	1.8	11
138	Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. <i>Gut</i> , 2022, , gutjnl-2022-327099.	6.1	11
139	Somatic second-hit mutations leads to polycystic liver diseases. <i>World Journal of Gastroenterology</i> , 2013, 19, 141.	1.4	10
140	Functional crosstalk between the adenosine transporter CNT3 and purinergic receptors in the biliary epithelia. <i>Journal of Hepatology</i> , 2014, 61, 1337-1343.	1.8	10
141	Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity. <i>Cell Death and Disease</i> , 2021, 12, 555.	2.7	10
142	DHEA Protects Human Cholangiocytes and Hepatocytes against Apoptosis and Oxidative Stress. <i>Cells</i> , 2022, 11, 1038.	1.8	10
143	Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry. <i>Cancers</i> , 2022, 14, 2389.	1.7	10
144	Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models. <i>Cancer Cell International</i> , 2012, 12, 5.	1.8	9

#	ARTICLE	IF	CITATIONS
145	Aging-Related Expression of Twinfilin-1 Regulates Cholangiocyte Biological Response to Injury. <i>Hepatology</i> , 2019, 70, 883-898.	3.6	9
146	New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	9
147	Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment. <i>Digestive Diseases</i> , 2017, 35, 275-281.	0.8	8
148	High fluorescence cell count in ascitic body fluids for carcinomatosis screening. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 272-274.	1.4	8
149	Development of new assays and improved procedures for the purification of recombinant human chymase. <i>FEBS Journal</i> , 2001, 268, 5885-5893.	0.2	7
150	Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease. <i>Hepatology</i> , 2021, 73, 186-203.	3.6	7
151	Inhibition of NAE-dependent protein hyperacetylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease. <i>United European Gastroenterology Journal</i> , 2021, 9, 848-859.	1.6	7
152	New Advances in the Molecular Mechanisms Driving Biliary Fibrosis and Emerging Molecular Targets. <i>Current Drug Targets</i> , 2017, 18, 908-920.	1.0	7
153	Cholangiocarcinoma: State-of-the-art knowledge and challenges. <i>Liver International</i> , 2019, 39, 5-6.	1.9	6
154	Cholangiocyte-to-Hepatocyte Differentiation: A Context-Dependent Process and an Opportunity for Regenerative Medicine. <i>Hepatology</i> , 2019, 69, 480-483.	3.6	6
155	Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. <i>Cancers</i> , 2020, 12, 3748.	1.7	6
156	Zolmitriptan: A Novel Portal Hypotensive Agent Which Synergizes with Propranolol in Lowering Portal Pressure. <i>PLoS ONE</i> , 2013, 8, e52683.	1.1	5
157	Usefulness of serum metabolic profiling in the search of novel diagnostic biomarkers for primary sclerosing cholangitis, intrahepatic cholangiocarcinoma and hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 68, S72-S73.	1.8	5
158	Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 377-388.	1.9	5
159	Molecular Mechanisms of Cholangiocarcinogenesis: New Potential Targets for Therapy. <i>Current Drug Targets</i> , 2017, 18, 932-949.	1.0	5
160	Toward personalized medicine for intrahepatic cholangiocarcinoma: Pharmacogenomic stratification of patients. <i>Hepatology</i> , 2018, 68, 811-814.	3.6	4
161	O-GlcNAcylation: Undesired tripmate but an opportunity for treatment in NAFLD-HCC. <i>Journal of Hepatology</i> , 2017, 67, 218-220.	1.8	3
162	Characterizing the Heterogeneity of Liver Cell Populations Under a NASH-Related Hepatotoxicant Using Single-Nuclei RNA Sequencing. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 294-296.	2.3	3

#	ARTICLE	IF	CITATIONS
163	Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-À-vis anti-SARS-CoV-2 antibodies from a high incidence region. <i>International Journal of Infectious Diseases</i> , 2021, 110, 114-122.	1.5	3
164	Editorial: bezafibrate in the treatment of patients with primary biliary cholangitis“are we there yet?. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 247-248.	1.9	3
165	Primers on Molecular Pathways “ Ion Channels: Key Regulators of Pancreatic Physiology. <i>Pancreatology</i> , 2009, 9, 556-559.	0.5	2
166	Cholangiocytes in health and disease: From basic science to novel treatments. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1217-1219.	1.8	2
167	Adaptive downregulation of Cl-/HCO3- exchange activity in rat hepatocytes under experimental obstructive cholestasis. <i>PLoS ONE</i> , 2019, 14, e0212215.	1.1	2
168	Applications of organoids in regenerative medicine: a proof-of-concept for biliary injury. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 371-372.	8.2	2
169	REPLY:. <i>Hepatology</i> , 2021, 74, 1129-1131.	3.6	2
170	p-STAT3 is a PDC-E2 interacting partner in human cholangiocytes and hepatocytes with potential pathobiological implications. <i>Scientific Reports</i> , 2021, 11, 21649.	1.6	2
171	More insight into the diversity of cholangiocyte ciliopathies. <i>Journal of Hepatology</i> , 2016, 65, 1083-1085.	1.8	1
172	REPLY:. <i>Hepatology</i> , 2021, 74, 2319-2321.	3.6	1
173	Fibrocystic Diseases of the Liver. , 2018, , 995-1014.e6.		1
174	PIGR-enriched circulating vesicles contributes to hepatocellular carcinoma aggressiveness. <i>Journal of Hepatology</i> , 2022, 76, 768-770.	1.8	1
175	Reply to: “Diagnostic and prognostic role of circulating microparticles in hepatocellular carcinoma“ <i>Journal of Hepatology</i> , 2018, 68, 203-204.	1.8	0
176	Reply to: “We need to talk about #livertwitter“ <i>Journal of Hepatology</i> , 2021, 75, 1240-1241.	1.8	0
177	Unscrambling a novel pathogenic role for interleukin-20 in acute hepatitis and bacterial infection: A double-edged sword?. <i>Journal of Hepatology</i> , 2021, 75, 22-24.	1.8	0
178	A look back at cholangiocarcinoma in Finland. <i>United European Gastroenterology Journal</i> , 2021, 9, 1103-1104.	1.6	0
179	Integrative Proposal for the Use of Biomarkers in Clinical Practice Management of NAFLD/NASH. , 2020, , 225-236.		0
180	Extracellular Vesicles in Non-alcoholic Fatty Liver Disease: Key Players in Disease Pathogenesis and Promising Biomarker Tools. , 2020, , 157-180.		0